A 1.0 ml syringe handles maintenance doses in one injection at this concentration, with a second small draw for higher doses
GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
for the 8 mg dose, these figures were 100%, 91%, and 75%
A good clinician will take the whole person into account and build a plan tailored to your body, health history, and goals
GLP-1 medications slow gastric emptying, meaning food and liquids remain in the stomach longer than normal
10.1111/dme.13066 23